11 August 2021 : Clinical Research
Outcomes in 36 Patients with Stage IIIA-N2 Squamous Cell Carcinoma of the Lung Treated with Nab-Paclitaxel Plus Carboplatin as Neoadjuvant Therapy: A Prospective Study from a Single Center
Jianquan Zhu1ABCDEF, Yu Zhang1BC, Meng Wang1BC, Zhenfa Zhang1BC, Dongsheng Yue1BC, Shichang Liu2BC, Yi Pan3BC, Changli Wang1AE*DOI: 10.12659/MSM.930738
Med Sci Monit 2021; 27:e930738
Table 3 Surgical characteristics and endpoints of patients with squamous cell carcinoma of the lung treated with neoadjuvant nab-paclitaxel and carboplatin.
| Variable | Surgery (n=23) |
|---|---|
| R0 resection, n (%) | 22 (95.7) |
| Adjuvant chemotherapy, n (%) | 21 (91.3) |
| Type of surgery, n (%) | |
| Lobectomy | 16 (69.6) |
| Bilobectomy | 3 (13.0) |
| Pneumonectomy | 4 (17.4) |
| pCR 1, (%)* | 2 (8.7) |
| pCR 2, (%)** | 2 (8.7) |
| MPR, (%) | 8 (34.8) |
| Downstage, (%) | 11 (47.8) |
| MPR – major pathological response; pCR – pathological complete response; R0 – margin-free. * pCR 1 represented the proportion of patients with pCR when considering the tumor only; ** pCR 2 represented the proportion of patients with pCR when considering the tumor and lymph nodes. | |